• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer

    Thumbnail
    View/ Open
    pone.0193131.pdf (6.135Mb)

    Show full item record
    
    Author
    White, Michael; Freistaedter, Andrew; Jones, Gwendolyn J B; Zervos, Emmanuel; Roper, Rachel L
    Abstract
    Pancreatic cancer is the 5th leading cause of cancer deaths, and there are no effective treatments. We developed a poxvirus platform vaccine with improved immunogenicity and inserted the mesothelin gene to create an anti-mesothelin cancer vaccine. Mesothelin expression is mostly restricted to tumors in adult mammals and thus may be a good target for cancer treatment. We show here that the modified vaccinia virus Ankara (MVA) virus expressing mesothelin and the enhanced MVA virus missing the immunosuppressive A35 gene and expressing mesothelin were both safe in mice and were able to induce IFN-gamma secreting T cells in response to mesothelin expressing tumor cells. In addition, the MVA virus has oncolytic properties in vitro as it can replicate in and kill Panc02 pancreatic adenocarcinoma cell line tumor cells, even though it is unable to replicate in most mammalian cells. Deletion of the A35 gene in MVA improved T cell responses as expected. However, we were unable to demonstrate inhibition of Panc02 tumor growth in immunocompetent mice with pre-vaccination of mice, boosts, or even intratumoral injections of the recombinant viruses. Vaccine efficacy may be limited by shedding of mesothelin from tumor cells thus creating a protective screen from the immune system.
    URI
    http://hdl.handle.net/10342/8523
    Date
    2018-02-23
    Citation:
    APA:
    White, Michael, & Freistaedter, Andrew, & Jones, Gwendolyn J B, & Zervos, Emmanuel, & Roper, Rachel L. (February 2018). Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer. PLoS ONE, (13:2), p.e0193131. Retrieved from http://hdl.handle.net/10342/8523

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    White, Michael, and Freistaedter, Andrew, and Jones, Gwendolyn J B, and Zervos, Emmanuel, and Roper, Rachel L. "Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer". PLoS ONE. 13:2. (e0193131.), February 2018. April 19, 2021. http://hdl.handle.net/10342/8523.
    Chicago:
    White, Michael and Freistaedter, Andrew and Jones, Gwendolyn J B and Zervos, Emmanuel and Roper, Rachel L, "Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer," PLoS ONE 13, no. 2 (February 2018), http://hdl.handle.net/10342/8523 (accessed April 19, 2021).
    AMA:
    White, Michael, Freistaedter, Andrew, Jones, Gwendolyn J B, Zervos, Emmanuel, Roper, Rachel L. Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer. PLoS ONE. February 2018; 13(2) e0193131. http://hdl.handle.net/10342/8523. Accessed April 19, 2021.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback